Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
1997-8-1
pubmed:abstractText
Among 936 demands for treatment by drug users in Greece in 7 months in 1994, 78 subjects making at least two demands were identified by code numbers. The median time between demands was 50 days (range 2-219). The data obtained by interview at the first two demands were compared to estimate the reliability of the interview schedule of the First Treatment Demand protocol of the Pompidou Group of the Council of Europe. Subjects were 84.6% male, with a median age of 27 years (range 14-43) and median duration of use 11 years (range 2-27). The primary substance of use was mainly heroin (88.5%). The percentage of agreement between interviews was highest for lifetime history of injecting (100%), urban residence (98.7%) and mode of use of heroin (94.3%). Percentages of agreement were close to 90% for most other items of socio-demographic data and drug use history, whether or not the correct response to the item could logically change between interviews. It is concluded that reliability of the data is around 90% and short-term behaviour in this population is rather stable. Only employment status (52.9% agreement) and secondary substance of abuse (25.5%) appeared to be exceptions. It is noteworthy that HIV and hepatitis serostatuses were reported less reliably than most other items.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0376-8716
pubmed:author
pubmed:issnType
Print
pubmed:day
14
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-61
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Reliability of drug dependents' self-reports.
pubmed:affiliation
National Focal Point on Drugs and Drug Abuse, University of Athens Medical School, Greece. akokke@leon.nrcps.ariadne-t.gr
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't